skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

Review

(2294) Views  (909) Full article downloads

Authors: Firas Badin, John Hayslip

Published Date April 2010 Volume 2010:2 Pages 37 - 45
DOI: http://dx.doi.org/10.2147/CEOR.S4221

Firas Badin, John Hayslip

University of Kentucky, Markey Cancer Center, Lexington, KY, USA

Abstract: Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma. This report focuses upon treatment efficacy, quality of life, and safety of rituximab or rituximab-containing regimens. More uniquely, we review economic aspects of lymphoma treatments, including the cost of standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in both induction and maintenance treatment, and lymphoma’s impacts on patient’s productivity and their caregivers. We conclude that adding rituximab to standard chemotherapy treatment for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings during both induction and maintenance therapies. Despite extensive review of the literature, many important questions have yet to be answered in the rituximab era and these represent important directions for future study.

Keywords: rituximab, lymphoma, cost effectiveness, transplant, safety








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The pathophysiology of bronchiectasis
Use of electronic medical records in oncology outcomes research
Cost-effectiveness analysis of intravenous levetiracetam versus intravenous phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic brain injury
Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
Pharmacoeconomic considerations in the treatment of breast cancer
Clinical and economic considerations of antiobesity treatment: a review of orlistat
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy